Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine novel explanation of cardiovascular side effects associated with anti-inflammatory drugs

Circulation

Volumn 131, Issue 7, 2015, Pages 633-642

  Ahmetaj Shala, Blerina ^a   Kirkby, Nicholas S ^a   Knowles, Rebecca ^b   Al'Yamani, Malak ^a,c   Mazi, Sarah ^c   Wang, Zhen ^d   Tucker, Arthur T ^b   Mackenzie, Louise ^e   Armstrong, Paul C J ^b   Nüsing, Rolf M ^f   Tomlinson, James A P ^d   Warner, Timothy D ^b   Leiper, James ^d   Mitchell, Jane A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^f GOETHE UNIVERSITY   (Germany)

Author keywords

Endothelium; Kidney; Nitric oxide; Pharmacology; Prostaglandins

Indexed keywords

CELECOXIB; CREATININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NAPROXEN; PARECOXIB; PROSTACYCLIN RECEPTOR; UREA; ANTIINFLAMMATORY AGENT; ARGININE; BIOLOGICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; N,N-DIMETHYLARGININE; PTGS2 PROTEIN, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HEART PROTECTION; HUMAN; KIDNEY MEDULLA; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR GENE; UREA BLOOD LEVEL; VASOMOTOR REFLEX; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; CARDIOVASCULAR DISEASES; DEFICIENCY; KNOCKOUT MOUSE; ORGAN CULTURE TECHNIQUE; YOUNG ADULT;

ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN CULTURE TECHNIQUES; YOUNG ADULT;

EID: 84923828761     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.011591     Document Type: Article

References (50)

1. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999; 96: 7563-7568.
2. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 2000; 119: 706-714.
3. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev. 2008; 88: 1547-1565. doi: 10.1152/physrev.00004.2008.
4. Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol. 1999; 128: 1121-1132. doi: 10.1038/sj.bjp.0702897.
5. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007; 115: 1634-1642. doi: 10.1161/ CIRCULATIONAHA.106.181424.
6. Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet. 2008; 371: 270-273. doi: 10.1016/S0140-6736(08)60137-3.
7. Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol. 2007; 50: 470-479. doi: 10.1097/ FJC.0b013e318157f72d.
8. McGettigan P, Henry D. Cardiovascular risk with non-steroidal antiinflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011; 8: e1001098. doi: 10.1371/journal. pmed.1001098.
9. Kohli P, Steg PG, Cannon CP, Smith SC Jr, Eagle KA, Ohman EM, Alberts MJ, Hoffman E, Guo J, Simon T, Sorbets E, Goto S, Bhatt DL; REACH Registry Investigators. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med. 2014; 127: 53-60.e1. doi: 10.1016/j.amjmed.2013.08.017.
10. Wong E, Huang JQ, Tagari P, Riendeau D. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis. 2001; 157: 393-402.
11. Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O, Warner TD, Mitchell JA. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A. 2012; 109: 17597-17602. doi: 10.1073/pnas.1209192109.
12. Liu B, Luo W, Zhang Y, Li H, Zhu N, Huang D, Zhou Y. Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries. Exp Physiol. 2012; 97: 277-289. doi: 10.1113/expphysiol.2011.062034.
13. Zidar N, Odar K, Glavac D, Jerse M, Zupanc T, Stajer D. Cyclooxygenase in normal human tissues-is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? J Cell Mol Med. 2009; 13(9B): 3753-3763. doi: 10.1111/j.1582-4934.2008.00430.x.
14. Kirkby NS, Zaiss AK, Urquhart P, Jiao J, Austin PJ, Al-Yamani M, Lundberg MH, MacKenzie LS, Warner TD, Nicolaou A, Herschman HR, Mitchell JA. LC-MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern reveals non-vascular sites of COX-2 expression. PLoS One. 2013; 8: e69524. doi: 10.1371/journal. pone.0069524.
15. Harris RC Jr. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol. 2002; 89(6A): 10D-17D.
16. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, Breyer MD. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002; 110: 61-69. doi: 10.1172/ JCI14752.
17. Khan KN, Paulson SK, Verburg KM, Lefkowith JB, Maziasz TJ. Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int. 2002; 61: 1210-1219. doi: 10.1046/j.1523-1755.2002.00263.x.
18. Harris RC. Physiologic and pathophysiologic roles of cyclooxygenase-2 in the kidney. Trans Am Clin Climatol Assoc. 2013; 124: 139-151.
19. Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. Cardiol Rev. 2011; 19: 184-191. doi: 10.1097/CRD.0b013e31821ddcf4.
20. Brater DC. Renal effects of cyclooxygyenase-2-selective inhibitors. J Pain Symptom Manage. 2002; 23(4 suppl): S15-S20; discussion S21.
21. Carmichael J, Shankel SW. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med. 1985; 78(6 pt 1): 992-1000.
22. Kömhoff M, Grone HJ, Klein T, Seyberth HW, Nüsing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol. 1997; 272(4 pt 2): F460-F468.
23. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999; 289: 735-741.
24. Singh G, Miller JD, Huse DM, Pettitt D, D'Agostino RB, Russell MW. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol. 2003; 30: 714-719.
25. Salvo F, Antoniazzi S, Duong M, Molimard M, Bazin F, Fourrier-Réglat A, Pariente A, Moore N. Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies. Expert Opin Drug Saf. 2014; 13: 573-585. doi: 10.1517/14740338.2014.907792.
26. Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z, Landesberg G, Crichton I, Wu W, Puré E, Funk CD, FitzGerald GA. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med. 2012; 4: 132ra54. doi: 10.1126/scitranslmed.3003787.
27. Kirkby NS, Lundberg MH, Chan MV, Vojnovic I, Solomon AB, Emerson M, Mitchell JA, Warner TD. Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide. Proc Natl Acad Sci U S A. 2013; 110: 15782-15787. doi: 10.1073/ pnas.1218880110.
28. Schuh CD, Pierre S, Weigert A, Weichand B, Altenrath K, Schreiber Y, Ferreiros N, Zhang DD, Suo J, Treutlein EM, Henke M, Kunkel H, Grez M, Nusing R, Brune B, Geisslinger G, Scholich K. Prostacyclin mediates neuropathic pain through interleukin 1beta-expressing resident macrophages. Pain. 2014; 155: 545-555.
29. Caplin B, Leiper J. Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators? Arterioscler Thromb Vasc Biol. 2012; 32: 1343-1353. doi: 10.1161/ATVBAHA.112. 247726.
30. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995; 378: 406-409. doi: 10.1038/378406a0.
31. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A, Stidwill R, McDonald NQ, Vallance P. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007; 13: 198-203. doi: 10.1038/nm1543.
32. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994; 94: 2504-2510. doi: 10.1172/JCI117620.
33. Stichtenoth DO, Frölich JC. COX-2 and the kidneys. Curr Pharm Des. 2000; 6: 1737-1753.
34. Wang D, Patel VV, Ricciotti E, Zhou R, Levin MD, Gao E, Yu Z, Ferrari VA, Lu MM, Xu J, Zhang H, Hui Y, Cheng Y, Petrenko N, Yu Y, FitzGerald GA. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci U S A. 2009; 106: 7548-7552. doi: 10.1073/ pnas.0805806106.
35. Papanicolaou KN, Streicher JM, Ishikawa TO, Herschman H, Wang Y, Walsh K. Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2. J Mol Cell Cardiol. 2010; 49: 196-209. doi: 10.1016/j. yjmcc.2010.04.002.
36. Lin WJ, Gary JD, Yang MC, Clarke S, Herschman HR. The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase. J Biol Chem. 1996; 271: 15034-15044.
37. Rodionov RN, Murry DJ, Vaulman SF, Stevens JW, Lentz SR. Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J Biol Chem. 2010; 285: 5385-5391. doi: 10.1074/jbc.M109.091280.
38. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1989; 86: 3375-3378.
39. Swierkosz TA, Mitchell JA, Sessa WC, Hecker M, Vane JR. L-glutamine inhibits the release of endothelium-derived relaxing factor from the rabbit aorta. Biochem Biophys Res Commun. 1990; 172: 143-148.
40. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, Zweier JL. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem. 2007; 282: 879-887. doi: 10.1074/jbc. M603606200.
41. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan RS. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009; 119: 1592-1600. doi: 10.1161/ CIRCULATIONAHA.108.838268.
42. Mügge A, Hanefeld C, Böger RH; CARDIAC study investigators. Plasma concentration of asymmetric dimethylarginine and the risk of coronary heart disease: rationale and design of the multicenter CARDIAC study. Atheroscler Suppl. 2003; 4: 29-32.
43. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Froelich JC. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol. 1999; 33: 652-658.
44. Lundman P, Eriksson MJ, Stühlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol. 2001; 38: 111-116.
45. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol. 2001; 37: 489-492.
46. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999; 99: 1141-1146.
47. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343: 1520-1528, 2 p following 1528. doi: 10.1056/NEJM200011233432103.
48. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352: 1092-1102. doi: 10.1056/ NEJMoa050493.
49. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006; 355: 873-884. doi: 10.1056/NEJMoa061355.
50. Lerman A, Burnett JC Jr, Higano ST, McKinley LJ, Holmes DR Jr. Longterm L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998; 97: 2123-2128.